First-in-human Phase 1 Study of CC-94676, a First-in-class Androgen Receptor (AR) Ligand-Directed Degrader (LDD), in Patients (pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc).

Dana E. Rathkopf,Manish R. Patel,Atish Dipankar Choudhury,Drew W. Rasco,Nehal J. Lakhani,Jessica E. Hawley,Ana Aparicio,Vivek Narayan,Sandy Srinivas,Karie Runcie,Hamid Emamekhoo,Zachery R. Reichert,Michael Anthony Carducci, Amber L. Wells, Can Liu,Raju Kandimalla, Jiaju Wu, Marie Huong Nguyen,Michael Pourdehnad,Andrew J. Armstrong

Journal of Clinical Oncology（2024）

引用 0|浏览11

关键词

283-2494-5577-2829-12292,261-566-148,261-137-7318-7319,283-2494-5577-2829-12292,3282-206-4957-3975-3408-6824,613-545-552,261-492-199-2823-10594-7548-5180,261-436,60,162,256,2946,143,1917,38092-18135,38092-18135

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要